FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088282011> ?p ?o ?g. }

• W2088282011 endingPage "2083" @default.
• W2088282011 startingPage "2082" @default.
• W2088282011 abstract "Rash is a common side-effect of nevirapine, a non-nucleoside reverse transcriptase inhibitor. The incidence of rash associated with the use of nevirapine has varied across different studies [1–5], being cited at 17% by the manufacturer (Viramune package insert; Roxane Laboratories, Inc., Columbus, Ohio, USA). Stevens-Johnson syndrome has also occurred in 0.5–1% of patients [5,6]. Most of the study subjects in trials of nevirapine were Caucasians [1,2,4]. Experience in our local Chinese patients showed an exceptionally high incidence of rash related to the use of this drug. Amongst the Chinese HIV-positive patients who had been observed for 8 weeks or more after commencing treatment with nevirapine, five (62.5%) out of eight patients had developed skin rash. The skin eruption occurring in our patients was a generalized, maculopapular rash, affecting the face, trunk and limbs. Fever was present in two patients. Although none had mucosal involvement, the rash was severe enough to warrant withholding nevirapine in all patients, after failure to improve on oral antihistamine. All resolved promptly upon withdrawal of the drug. None of the patients were rechallenged. Nevirapine was given as part of triple therapy in all eight patients, either with zidovudine—didanosine or stavudine—didanosine. None had any history of drug allergy. All patients had a lead-in period of 14 days during which 200 mg nevirapine was given once daily, a dosage recommended to lessen the frequency of rash (Viramune package insert; Roxane Laboratories). In one patient the rash appeared after 11 days of treatment. For the other patients, the rash began in weeks 3 and 4 of treatment, when the dosage of nevirapine was increased to 200 mg twice daily. Liver function tests were checked for four of the five patients at the time of rash. Three patients had raised enzyme levels compared with their normal prenevirapine baseline. Their alanine aminotransferase level ranged from 93 to 266 U/l, alkaline phosphatase from 48 to 608 U/l, and total bilirubin from 22 to 124 μmol/l. For the fourth patient, liver function did not show any deterioration from a midly abnormal baseline. The median CD4 cell count in the five patients who developed rash was 229 × 106/l, comparable to the CD4 cell count of 284 × 106/l in the other three patients who did not have rash within the first 8 weeks of treatment. Three patients in the first group were men, whereas all were men in the latter group. Median body weights were 62.0 and 69.3 kg, respectively. Three patients who developed rash were treatmentnaive, compared with two out of those who did not have rash. For the other patients, nevirapine was added to the pre-existing regimen as consolidation of treatment. It is unlikely that the rash was related to the nucleoside analogues rather than to nevirapine. Zidovudine, didanosine and stavudine have been extensively used in our local patients and drug rash had been a rare event. In summary, a high incidence of hypersensitivity reaction had been observed among Chinese patients treated with nevirapine. Whether there is any definite association has yet to be proven. Physicians, meanwhile, should be cautioned about this problem when prescribing nevirapine to their Chinese HIV-positive patients." @default.
• W2088282011 created "2016-06-24" @default.
• W2088282011 creator A5004148540 @default.
• W2088282011 creator A5011267202 @default.
• W2088282011 creator A5016917968 @default.
• W2088282011 creator A5041164194 @default.
• W2088282011 date "1998-10-01" @default.
• W2088282011 modified "2023-09-24" @default.
• W2088282011 title "High incidence of nevirapine-associated rash in HIV-infected Chinese" @default.
• W2088282011 cites W2034280823 @default.
• W2088282011 cites W2048776156 @default.
• W2088282011 cites W2123101436 @default.
• W2088282011 cites W2137262613 @default.
• W2088282011 cites W2165253161 @default.
• W2088282011 doi "https://doi.org/10.1097/00002030-199815000-00026" @default.
• W2088282011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9814883" @default.
• W2088282011 hasPublicationYear "1998" @default.
• W2088282011 type Work @default.
• W2088282011 sameAs 2088282011 @default.
• W2088282011 citedByCount "30" @default.
• W2088282011 countsByYear W20882820112012 @default.
• W2088282011 countsByYear W20882820112013 @default.
• W2088282011 countsByYear W20882820112014 @default.
• W2088282011 countsByYear W20882820112015 @default.
• W2088282011 countsByYear W20882820112019 @default.
• W2088282011 crossrefType "journal-article" @default.
• W2088282011 hasAuthorship W2088282011A5004148540 @default.
• W2088282011 hasAuthorship W2088282011A5011267202 @default.
• W2088282011 hasAuthorship W2088282011A5016917968 @default.
• W2088282011 hasAuthorship W2088282011A5041164194 @default.
• W2088282011 hasBestOaLocation W20882820111 @default.
• W2088282011 hasConcept C120665830 @default.
• W2088282011 hasConcept C121332964 @default.
• W2088282011 hasConcept C126322002 @default.
• W2088282011 hasConcept C142462285 @default.
• W2088282011 hasConcept C16005928 @default.
• W2088282011 hasConcept C203014093 @default.
• W2088282011 hasConcept C2776452011 @default.
• W2088282011 hasConcept C2777351918 @default.
• W2088282011 hasConcept C2777447569 @default.
• W2088282011 hasConcept C2778570526 @default.
• W2088282011 hasConcept C2779130552 @default.
• W2088282011 hasConcept C2779889181 @default.
• W2088282011 hasConcept C2780216070 @default.
• W2088282011 hasConcept C2780727368 @default.
• W2088282011 hasConcept C2993143319 @default.
• W2088282011 hasConcept C3013748606 @default.
• W2088282011 hasConcept C61511704 @default.
• W2088282011 hasConcept C71924100 @default.
• W2088282011 hasConceptScore W2088282011C120665830 @default.
• W2088282011 hasConceptScore W2088282011C121332964 @default.
• W2088282011 hasConceptScore W2088282011C126322002 @default.
• W2088282011 hasConceptScore W2088282011C142462285 @default.
• W2088282011 hasConceptScore W2088282011C16005928 @default.
• W2088282011 hasConceptScore W2088282011C203014093 @default.
• W2088282011 hasConceptScore W2088282011C2776452011 @default.
• W2088282011 hasConceptScore W2088282011C2777351918 @default.
• W2088282011 hasConceptScore W2088282011C2777447569 @default.
• W2088282011 hasConceptScore W2088282011C2778570526 @default.
• W2088282011 hasConceptScore W2088282011C2779130552 @default.
• W2088282011 hasConceptScore W2088282011C2779889181 @default.
• W2088282011 hasConceptScore W2088282011C2780216070 @default.
• W2088282011 hasConceptScore W2088282011C2780727368 @default.
• W2088282011 hasConceptScore W2088282011C2993143319 @default.
• W2088282011 hasConceptScore W2088282011C3013748606 @default.
• W2088282011 hasConceptScore W2088282011C61511704 @default.
• W2088282011 hasConceptScore W2088282011C71924100 @default.
• W2088282011 hasIssue "15" @default.
• W2088282011 hasLocation W20882820111 @default.
• W2088282011 hasLocation W20882820112 @default.
• W2088282011 hasLocation W20882820113 @default.
• W2088282011 hasOpenAccess W2088282011 @default.
• W2088282011 hasPrimaryLocation W20882820111 @default.
• W2088282011 hasRelatedWork W2001744429 @default.
• W2088282011 hasRelatedWork W2027214732 @default.
• W2088282011 hasRelatedWork W2086234324 @default.
• W2088282011 hasRelatedWork W2088282011 @default.
• W2088282011 hasRelatedWork W2101623279 @default.
• W2088282011 hasRelatedWork W2109940476 @default.
• W2088282011 hasRelatedWork W2154622620 @default.
• W2088282011 hasRelatedWork W2172558426 @default.
• W2088282011 hasRelatedWork W233229719 @default.
• W2088282011 hasRelatedWork W2085130205 @default.
• W2088282011 hasVolume "12" @default.
• W2088282011 isParatext "false" @default.
• W2088282011 isRetracted "false" @default.
• W2088282011 magId "2088282011" @default.
• W2088282011 workType "article" @default.